aspirin

Virtual ACC 2020 | VOYAGER PAD: Rivaroxaban Superior to Aspirin in Preventing Events

In patients with peripheral artery disease undergoing revascularization, the combination of rivaroxaban (Xarelto) and low doses of aspirin are superior to aspirin alone in the prevention of acute low limb ischemic events, amputation, cardiovascular events and strokes. The outcomes of VOYAGER PAD add to the COMPASS outcomes, showing the combination of therapies can benefit risk<a href="https://solaci.org/en/2020/03/31/virtual-acc-2020-voyager-pad-rivaroxaban-superior-to-aspirin-in-preventing-events/" title="Read more" >...</a>

ARTE: ¿AsEl fin de la aspirina para los pacientes anticoagulados que reciben angioplastiapirina o aspirina más clopidogrel post TAVI?

Alternatives for Patients Allergic to Aspirin

Intolerance to aspirin is relatively frequent and there is no other non-steroid anti-inflammatory medication to replace it. The new guidelines of chronic coronary syndromes make class IIb recommendations to use prasugrel or ticagrelor in aspirin-intolerant patients. This is not meant to replace dual antiaggregation therapy in aspirin intolerant patients, when needed; it is just a<a href="https://solaci.org/en/2020/03/02/alternatives-for-patients-allergic-to-aspirin/" title="Read more" >...</a>

AHA 2019 | TWILIGHT: discontinuar la aspirina luego de un síndrome coronario agudo

AHA 2019 | TWILIGHT: Discontinue Aspirin after Acute Coronary Syndrome

This study findings confirm less bleeding at no extra cost of thrombotic events when aspirin is discontinued after an acute coronary syndrome (ACS).  In the same line as the original TWILIGHT, this study focused on ACS patients alone (excluding STEMI) and confirmed that aspirin discontinuation after 3-month DAPT to continue with ticagrelor alone, reduced the<a href="https://solaci.org/en/2019/11/20/aha-2019-twilight-discontinue-aspirin-after-acute-coronary-syndrome/" title="Read more" >...</a>

indicación de tratamiento con estatinas

Statins in Primary Prevention: As Questioned as Aspirin?

This new review, recently published in BMJ, questions the benefit of statins in low-risk primary prevention patients. Authors argue that statins should be more cautiously indicated in primary prevention, considering that their absolute benefit is almost marginal in low-risk patients. Changes in the European guidelines have translated into a wide expansion of patients eligible for<a href="https://solaci.org/en/2019/11/05/statins-in-primary-prevention-as-questioned-as-aspirin/" title="Read more" >...</a>

Sangrados mayores en pacientes con AAS más rivaroxabán

Major Bleeding in Patients with Aspirin Plus Rivaroxaban

The combination of coronary artery disease or peripheral vascular disease and a reason for anticoagulation, such as atrial fibrillation, results in many patients who receive antiplatelet therapy with aspirin plus anticoagulation with rivaroxaban, for example. It is a well-known fact that this combination (aspirin 100 mg per day plus rivaroxaban 2.5 mg twice per day) reduces cardiovascular<a href="https://solaci.org/en/2019/10/16/sangrados-mayores-en-pacientes-con-aas-mas-rivaroxaban-2/" title="Read more" >...</a>

Sangrados mayores en pacientes con AAS más rivaroxabán

Major Bleeding in Patients with Aspirin Plus Rivaroxaban

The combination of coronary artery disease or peripheral vascular disease and a reason for anticoagulation, such as atrial fibrillation, results in many patients who receive antiplatelet therapy with aspirin plus anticoagulation with rivaroxaban, for example. It is a well-known fact that this combination (aspirin 100 mg per day plus rivaroxaban 2.5 mg twice per day) reduces cardiovascular<a href="https://solaci.org/en/2019/10/16/major-bleeding-in-patients-with-aspirin-plus-rivaroxaban/" title="Read more" >...</a>

Highlights TCT 2019

TCT 2019 | AUGUSTUS ACS: Apixaban vs. Warfarin and Aspirin vs. Placebo in AF and ACS

Courtesy of SBHCI. The safety and efficacy of antithrombotic and antiplatelet treatments in patients with atrial fibrillation admitted with acute coronary syndrome (who receive medical treatment or angioplasty) may vary from that in patients undergoing elective treatment. At 14&nbsp;days from elective angioplasty or hospitalization due to acute coronary syndrome, patients were randomized in a 2×2<a href="https://solaci.org/en/2019/09/30/tct-2019-augustus-acs-a-2x2-factorial-randomized-trial-of-apixaban-vs-warfarin-and-aspirin-vs-placebo-in-patients-with-atrial-fibrillation-and-an-acute-coronary-syndrome/" title="Read more" >...</a>

ticagrelor vs. aspirina

Aspirin in Primary Prevention: Another “Trendy” Topic in Publications

Aspirin is the standard treatment when it comes to optimal medical treatment in the context of secondary prevention of coronary artery disease, in patients with diagnosed, established atherosclerosis. Even though bleeding risk is rather small in the short period an acute event takes place, it increases substantially over time. However, the evidence clearly supports the<a href="https://solaci.org/en/2019/06/14/aspirin-in-primary-prevention-another-trendy-topic-in-publications/" title="Read more" >...</a>

ACC 2019 | SMART-CHOICE: la aspirina cada vez más “contra las cuerdas”

ACC 2019 | SMART-CHOICE: Aspirin Increasingly “Against the Ropes”

This work (presented during the same American College of Cardiology [ACC] 2019 Scientific Session as the STOPDAPT-2 trial) enrolled 2993 patients who underwent angioplasty with current-generation stents Xience, Promus, Synergy, or Orsiro at 33 Korean sites. Patients were randomized to 12 months of dual antiplatelet therapy or dropping aspirin at 3 months. There was no difference between the short-<a href="https://solaci.org/en/2019/03/25/acc-2019-smart-choice-aspirin-increasingly-against-the-ropes/" title="Read more" >...</a>

ARTE: ¿AsEl fin de la aspirina para los pacientes anticoagulados que reciben angioplastiapirina o aspirina más clopidogrel post TAVI?

Aspirin, Bleeding and Cardiovascular Events in Healthy Elderly

The ASCEND and ARRIVE trials -presented at the European Cardiology Congress and published in The New England Journal of Medicine (NEJM) and The Lancet respectively- have put against the ropes the indication of aspirin in the context of primary prevention. The ASPREE trial, recently published in the NEJM, appears to have definitely overthrown aspirin, since<a href="https://solaci.org/en/2018/12/04/aspirin-bleeding-and-cardiovascular-events-in-healthy-elderly/" title="Read more" >...</a>

Top